Immunothrombosis: Bridging endothelial dysfunction and no-reflow in ischemic stroke

Area of Science:

• Neuroscience
• Immunology
• Cardiovascular Medicine

Background:

• Acute ischemic stroke treatment relies on restoring blood flow.
• The "no-reflow" phenomenon hinders long-term benefits of recanalization therapies.
• Immunothrombosis, involving platelet-neutrophil aggregation and microvascular clots, drives the no-reflow phenomenon.

Purpose of the Study:

• To elaborate on the mechanisms of endothelial inflammation in the no-reflow cascade.
• To recommend targeting immunothrombosis for improved stroke management.

Main Methods:

• Review of pathological mechanisms.
• Elaboration on the role of endothelial inflammation.
• Discussion of immunothrombosis as a therapeutic target.

Main Results:

• Endothelial inflammation initiated or promoted by brain ischemia plays a key role in the no-reflow cascade.
• Immunothrombosis is identified as a critical pathological driver of the no-reflow phenomenon.

Conclusions:

• Targeting immunothrombosis is a promising strategy to mitigate the no-reflow phenomenon.
• Optimizing stroke management can be achieved by addressing immunothrombosis and endothelial inflammation.